PRNewsWire
23 Oct 2025, 14:00 UTC · 51w ago
Impact · against what's priced in
Jasper Therapeutics faces a new class action lawsuit alleging federal securities law violations during a period spanning late 2023 to mid-2025. This introduces potential legal liabilities and management distractions for the clinical-stage biotech firm.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish
A class action lawsuit has been filed against Jasper Therapeutics, Inc. (JSPR) and certain officers alleging violations of federal securities laws.
More negative than 94% of claims this week
The lawsuit covers a class period for securities purchases between November 30, 2023, and July 3, 2025.
Continue reading
5 related stories
The filing of a class action lawsuit alleging securities law violations creates new legal uncertainty and potential financial liabilities for the company.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 68% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is the subject of a class action lawsuit alleging violations of federal securities laws.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
5h ago
—
No price for JSPR right now — the quote feed didn't answer.
JSPR chart →
